The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -17,106 | -9,881 | -27,129 | -71,015 |
| Depreciation | 8,780 | 8,763 | 8,803 | 18,506 |
| Amortization of convertible debt discount | - | 374 | 372 | 1,164 |
| Amortization of debt issuance costs | - | 9 | 9 | 69 |
| Loss (gain) on disposal of assets, net | - | -31 | - | - |
| Impairment charges (note 5) | - | - | 7,086 | 20,041 |
| Amortization of intangibles | 7,633 | 7,632 | 7,634 | 16,486 |
| Impairment charges (note 3 and note 7) | - | 27,753 | - | - |
| Other impairment charges | - | - | 0 | 0 |
| Stock-based compensation | 9,636 | 8,042 | 10,306 | 22,968 |
| Impairment of long-lived assets | - | 0 | - | - |
| Non-cash operating lease expense | 1,720 | 1,713 | 1,686 | 3,353 |
| Other adjustments | 402 | -326 | 343 | -340 |
| Accounts receivable, net | 8,182 | 4,207 | 2,368 | -397 |
| Inventories | 1,271 | 28 | -5,632 | 7,147 |
| Prepaid and other assets | 1,395 | -3,205 | 514 | 1,136 |
| Operating lease liabilities | -1,299 | -1,233 | -795 | -187 |
| Deferred income tax liabilities, net | 769 | 2,694 | -869 | 1,534 |
| Accrued compensation | -7,004 | -4,098 | 2,773 | -14,340 |
| Accounts payable and other liabilities | 718 | -6,585 | -5,823 | 7,718 |
| Net cash used in operating activities | -8,137 | 1,343 | 8,884 | -4,997 |
| Proceeds from assets held for sale, net of closing costs | - | 2,066 | - | - |
| Purchases of marketable securities | - | 0 | - | - |
| Business acquisitions, net of cash acquired | - | 0 | 463 | 5,991 |
| Proceeds from maturities of marketable securities | 0 | 0 | 9,000 | 11,060 |
| Purchase of convertible note | - | 500 | - | - |
| Purchase of equity securities | - | 0 | 500 | - |
| Purchases of property and equipment | 5,000 | 7,871 | 8,314 | 10,823 |
| Net cash (used in) provided by investing activities | -5,000 | -6,305 | -277 | -5,754 |
| Repayment of convertible debt | - | 0 | 0 | 201,250 |
| Repayment of equipment financing obligations | - | 0 | - | - |
| Issuance of common stock, net | -338 | 431 | 765 | -234 |
| Net cash (used in) provided by financing activities | -338 | 431 | 765 | -201,484 |
| Net change in cash and cash equivalents | -13,475 | -4,531 | 9,372 | -212,235 |
| Less net change in cash classified within current assets held for sale | - | - | 22 | -54 |
| Net change in cash and cash equivalents | - | - | 9,394 | -212,289 |
| Cash and cash equivalents, beginning of period | 159,618 | 164,117 | 367,012 | - |
| Cash and cash equivalents, end of period | 146,143 | 159,618 | 164,117 | - |
NEOGENOMICS INC (NEO)
NEOGENOMICS INC (NEO)